ex-vivo autologous hematopoietic stem cell therapy (Cellectis)

N/A

Report date: 2025/03/20 16:00:02

Base Information

Drug Nameex-vivo autologous hematopoietic stem cell therapy (Cellectis)
Drug Alias Nameex vivo STAT3-transduced autologous hematopoietic stem cell therapy (Cellectis)
ClassificationCell and gene therapy > Cell therapy > Stem cell therapy > Hematopoietic stem cells therapy
Mechanisms of ActionSignal transducer and activator of transcription 3 stimulants
TargetsSignal transducer and activator of transcription 3
Therapy Area/IndicationsImmunologic Deficiency Syndromes
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryFrance
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesCellectis Sa
China Registration ClassN/A

Develop Information

Active CompaniesCellectis Sa
Inactive CompaniesN/A
Active IndicationsImmunologic Deficiency Syndromes
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A